Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [982]
News [2878]
Articles [137]
Editorials [3]
Conferences [93]
elearning [27]

Omics, early detection and novel therapies: Q & A

Dr Murrell and Dr Pardo
Omics, early detection and novel therapies: Q & A ( Dr Murrell and Dr Pardo )
5 Oct 2016

Immunotherapy in NSCLC

Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA
Immunotherapy in NSCLC ( Prof Giuseppe Giaccone - Georgetown University, Washington DC, USA )
5 Oct 2016

Immunotherapy in SCLC

Prof Dean Fennell - University of Leicester, Leicester, UK
Immunotherapy in SCLC ( Prof Dean Fennell - University of Leicester, Leicester, UK )
5 Oct 2016

Omics, early detection and novel therapies: Metabolomics

Dr Olivier Pardo - Imperial College London, London, UK
Omics, early detection and novel therapies: Metabolomics ( Dr Olivier Pardo - Imperial College London, London, UK )
5 Oct 2016

Small cell lung cancer: Q & A

Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson
Small cell lung cancer: Q & A ( Prof Gordon McVie, Prof Caroline Dive, Dr Fiona Blackhall and Dr Marianne Nicolson )
5 Oct 2016

Omics, early detection and novel therapies: Epigenetic studies

Dr Adele Murrell - University of Bath, Bath, UK
Omics, early detection and novel therapies: Epigenetic studies ( Dr Adele Murrell - University of Bath, Bath, UK )
5 Oct 2016

Small cell lung cancer: New therapies

Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK
Small cell lung cancer: New therapies ( Dr Fiona Blackhall - The Christie NHS Foundation Trust, Manchester, UK )
5 Oct 2016

Small cell lung cancer: Current standards of care

Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK
Small cell lung cancer: Current standards of care ( Dr Marianne Nicolson - Aberdeen Royal Infirmary, Aberdeen, UK )
5 Oct 2016

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK
We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016

Maintenance in NSCLC: Arguments against

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France
Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )
5 Oct 2016

Maintenance in NSCLC: Arguments for

Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK
Maintenance in NSCLC: Arguments for ( Dr Jaishree Bhosle - The Royal Marsden NHS Foundation Trust, London, UK )
5 Oct 2016

Maintenance in NSCLC: Q & A

Dr Besse and Dr Bhosle
Maintenance in NSCLC: Q & A ( Dr Besse and Dr Bhosle )
5 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation